Is it still effective to reduce the dose of Sotorasib?

Sotorasib is an oral small molecule inhibitor targeting KRAS G12C mutations. It is mainly used to treat malignant tumors such as non-small cell lung cancer (NSCLC) with KRAS G12C mutations. The drug has been proven to have clear efficacy in multiple clinical trials at standard doses (such as 960mg/day). However, during actual clinical use, some patients had to reduce the dosage due to adverse reactions, comorbidities, or special physical conditions, etc., which caused many patients to question whether "it is still effective after reducing the dosage."

Existing research and clinical observations show that sotorasib may still retain some of its efficacy after reduced dosage, especially if the drug's blood concentration can still cover the effective inhibitory level. Some patients who are intolerant of the 960 mg dose still maintain stable disease or remission after reducing the dosage to 720 mg or 480 mg. This is related to the persistence of KRAS G12C target inhibition and individual differences. However, it should be noted that the efficacy may be reduced, especially for patients with higher tumor burden or rapid disease progression, and the anti-tumor intensity after dose reduction may be insufficient.

In addition, most of the adverse reactions of sotoraxib are controllable, such as diarrhea, nausea, elevated transaminases, etc. Doctors usually determine whether temporary discontinuation, dose reduction, or auxiliary treatment is needed based on the severity. In many cases, after short-term adjustment or combined drug support, patients still have the opportunity to return to the recommended dose and continue treatment, thereby maintaining longer-term relief. Therefore, it is not advisable to blindly take low doses for a long time and should be dynamically adjusted under the guidance of a doctor.
In short, taking sotoraxib at a reduced dose may still be effective in certain circumstances, but it is not the best choice. Standard dosage can provide more stable target inhibition and disease control effects. If the dose needs to be reduced due to side effects or other problems, patients are advised to follow up closely, undergo regular imaging examinations, and maintain communication with their oncologists to ensure that the treatment plan strikes a reasonable balance between safety and efficacy.
Reference: https://www.lumakras.com/